JOURNAL OF ADVANCED ELECTRICAL AND ELECTRONIC ENGINEERING

Vol 1 Issue 3 (2025)

http://jaeee.org/

Predictive Value of Liver Biomarkers in Assessing Severity of RNA Virus-Related Chronic Liver Disease

Elena R. Vasquez

Department of Hepatology and Virology, Medical University of Vienna, Austria

Email: evasquez@meduni-vienna.ac.at

Abstract

RNA-based viruses such as hepatitis C virus (HCV) and hepatitis E virus (HEV) are principal etiological agents of chronic liver disease (CLD) worldwide, particularly in low- and middle-income countries. Liver function biomarkers, especially enzymatic and synthetic indices, serve as accessible and cost-effective tools for assessing hepatic injury, disease progression, and treatment response. This article explores the predictive value of transaminases (ALT, AST), cholestatic markers (ALP, GGT, bilirubin), and synthetic markers (albumin, prothrombin time) in stratifying the severity of chronic liver dysfunction associated with HCV and HEV. Through molecular and clinical insights, the study highlights how biomarker patterns can serve as proxies for viral activity, fibrosis progression, and hepatic decompensation. An evidence-based framework is proposed for their interpretation in both diagnostic and prognostic contexts.

Keywords

Hepatitis C Virus (HCV), Hepatitis E Virus (HEV), Liver Function Biomarkers, Chronic Liver Disease (CLD), Transaminases, Prognostic Indicators

INTRODUCTION

Chronic infections with RNA-based hepatitis viruses, especially HCV and chronic HEV, continue to burden global health systems, leading to cirrhosis, hepatocellular carcinoma, and liver failure. In the absence of early and invasive diagnostic measures, liver enzyme biomarkers offer a noninvasive yet reliable approach to detect, monitor, and predict disease severity. This article investigates the dynamic relationship between viral burden and liver function indices, seeking to establish their predictive value in clinical hepatology.

Molecular Pathogenesis of RNA Hepatitis Viruses

RNA hepatitis viruses such as **Hepatitis C virus (HCV)** and **Hepatitis E virus (HEV)** are significant contributors to both acute and chronic liver pathology globally. Their **molecular architecture and replication dynamics** govern their pathogenic potential, tissue specificity (hepatotropism), and capacity for chronic infection.

Hepatitis C Virus (HCV)

Structure and Genome:
HCV is a small, enveloped, positive-sense single-stranded RNA virus (~9.6 kb) classified under the Flaviviridae family. Its genome encodes a single polyprotein processed into structural proteins (Core, E1, and E2) and non-structural (NS2–NS5B) proteins. The viral envelope contains E1 and E2 glycoproteins, which mediate entry into hepatocytes via receptors such as **CD81**, **SR-B1**, **claudin-1**, and **occludin**.

Replication Strategy:
Following receptor-mediated endocytosis, HCV RNA is released into the cytoplasm and translated into a polyprotein, which is cleaved by viral and host proteases. The replication complex forms on **endoplasmic reticulum-derived membranes**, generating negative-strand intermediates that serve as templates for new viral genomes. RNA-dependent RNA polymerase (NS5B) lacks proofreading activity, contributing to HCV's high mutation rate and quasi-species diversity.

Chronicity Mechanisms:
HCV evades immune clearance through:

- **Rapid mutation** in antigenic sites.
- **Suppression of interferon signaling** via NS3/4A protease cleavage of MAVS.
- **Induction of T cell exhaustion**, mediated by upregulation of inhibitory receptors (PD-1, CTLA-4).
  These mechanisms allow **persistent replication**, resulting in chronic inflammation, fibrosis, and hepatocellular carcinoma in 20–30% of patients over decades.

Hepatitis E Virus (HEV)

Structure and Genome:
HEV is a non-enveloped, positive-sense RNA virus (~7.2 kb) belonging to the Hepeviridae family. Its genome comprises three open reading frames (ORFs):

- **ORF1**: Encodes non-structural proteins involved in replication.
- **ORF2**: Encodes the viral capsid protein.
- **ORF3**: Involved in vision egress and host interaction.

Replication Strategy:
HEV enters hepatocytes via endocytosis, though the exact receptors remain less defined. Replication occurs in the cytoplasm with transcription of a capped subgenomic RNA from which ORF2 and ORF3 proteins are synthesized. The **release of quasi-enveloped HEV particles** in blood (as opposed to non-enveloped fecal visions) contributes to immune evasion.

Hepatotropism and Chronicity:
HEV exhibits **strict hepatotropism**, primarily replicating in the liver and bile duct epithelium. While most infections are self-limiting, **chronic infection can occur** in immunocompromised individuals, particularly with **genotype 3**. Mechanisms include:

- **Impaired innate immunity** in transplant recipients.
- **Limited cytotoxic T-cell responses** due to immunosuppressive therapy.
- **ORF3-mediated inhibition of type I interferon signaling**.

Conclusion

Both HCV and HEV possess distinct structural and replication features that enable hepatocellular infection and, in select host environments, chronicity. Their interaction with host immune pathways underlies the **pathogenesis of progressive liver damage**, fibrosis, and in some cases, liver failure. Understanding these mechanisms remains pivotal for developing targeted antiviral therapies and immunomodulatory strategies.

Therapeutic Monitoring and Treatment Response

Effective management of chronic hepatitis C virus (HCV) and hepatitis E virus (HEV) infections—especially in immunocompromised or treatment-eligible individuals—relies on continuous assessment of **liver function biomarkers**. These biomarkers offer real-time insights into hepatic injury, regeneration, and overall response to antiviral therapy. In clinical hepatology, the **normalization patterns** of specific enzymes and synthetic markers serve not only as therapeutic milestones but also as **predictors of long-term outcomes**.

Biomarker Normalization in HCV Therapy

The advent of **direct-acting antivirals (DAAs)** has revolutionized HCV treatment, achieving sustained virological response (SVR) rates exceeding 95%. A hallmark of treatment success is the **rapid normalization of serum alanine aminotransferase (ALT)** and aspartate aminotransferase (AST) levels within weeks of therapy initiation. Studies have shown that:

- **ALT normalization at week 4 (rapid biochemical response)** correlates with a **favorable immune reconstitution** and **lower risk of hepatic decompensation**.
- Persistent elevations despite virologic suppression may suggest **coexisting liver damage**, such as steatohepatitis or autoimmune overlap.

- Decreases in bilirubin and gamma-glutamyl transferase (GGT) levels often accompany transaminase improvement, indicating resolution of hepatocellular stress and cholestasis.

Albumin and prothrombin time (PT) improvement is observed more gradually, reflecting enhanced hepatic synthetic function post-viral clearance. These changes are particularly meaningful in cirrhotic patients, where early synthetic recovery forecasts **lower MELD scores and better transplant-free survival**.

Monitoring HEV in Immunocompromised Hosts

Chronic HEV, particularly genotype 3, remains a therapeutic challenge in **solid organ transplant recipients** and other immunosuppressed patients. Ribavirin remains the mainstay of antiviral therapy. In such cases:

- **ALT decline within 2–4 weeks** of ribavirin therapy indicates effective viral suppression.
- A **failure to normalize ALT and persistently detectable HEV RNA beyond 12 weeks** is predictive of treatment failure or relapse.
- Gradual recovery of albumin levels and decline in total bilirubin post-treatment are **prognostic of immune reconstitution** and mucosal clearance.

As with HCV, **early biochemical response** is significantly associated with **sustained virologic response (SVR)**, making enzyme monitoring an essential, low-cost tool in follow-up protocols.

Prognostic Implications

The utility of liver biomarkers extends beyond immediate treatment response:

- **ALT normalization** by week 4 serves as an **early surrogate endpoint** for clinical trials and patient monitoring.
- **Improvements in albumin and PT** are correlated with **reversal of hepatic dysfunction** and **decreased risk of hepatic encephalopathy**.
- **Non-normalization** despite virologic response necessitates evaluation for **concomitant liver pathology** or drug-induced liver injury (DILI).

Incorporating dynamic biomarker monitoring into clinical algorithms allows for **personalized treatment adjustments**, **early identification of non-responders**, and **timely intervention to prevent hepatic deterioration**.

Conclusion

Biochemical monitoring of liver function plays a pivotal role in assessing **antiviral treatment efficacy** in RNA virus-associated chronic liver disease. The early and sustained normalization of transaminases, bilirubin, and synthetic markers not only confirms virological success but also

offers **prognostic insight into hepatic recovery**. As antiviral regimens evolve, the role of these inexpensive yet highly informative biomarkers will remain central in optimizing treatment paradigms and improving patient outcomes.

Recommendations for Biomarker-Based Surveillance

In the context of chronic liver disease (CLD) induced by **RNA viruses such as HCV and HEV**, the integration of biomarker-based surveillance into routine clinical care is essential for **early diagnosis, therapeutic monitoring, and long-term management**. A structured, cost-effective, and pathogen-specific surveillance strategy ensures optimized outcomes, especially in **low- and middle-income countries (LMICs)** where resources are constrained and disease burden is disproportionately high.

1. Initial Screening Protocols

For newly diagnosed or at-risk individuals, the following initial biomarker panel is recommended:

- **Serum ALT and AST**: First-line indicators of hepatocellular injury.
- **Total and direct bilirubin**: To assess hepatic clearance and cholestatic involvement.
- **Serum albumin and prothrombin time (INR)**: Evaluate synthetic liver function.
- **HCV RNA or HEV RNA PCR quantification**: To confirm active infection and assess viral load.

These baseline markers form the foundation for determining **disease severity**, eligibility for treatment, and urgency of intervention.

2. Stratified Follow-Up in HCV Patients

Patients undergoing treatment with **direct-acting antivirals (DAAs)** for HCV should be monitored at:

- **Week 4**: ALT/AST normalization as a marker of early response.
- **Week 8–12**: Further transaminase decline, bilirubin stabilization, and synthetic function improvement.
- **Post-treatment week 12 (SVR12)**: Sustained virological response confirmation with full biochemical panel reassessment.

For cirrhotic patients or those with prior decompensation, **biannual assessments** of albumin, bilirubin, and PT/INR are critical for detecting subclinical progression.

3. Surveillance for Chronic HEV Infections

In immunocompromised patients with chronic HEV (especially genotype 3), the following is advised:

- **Monthly ALT and HEV RNA quantification** during ribavirin therapy.
- **Monitoring of albumin and bilirubin levels** for hepatic recovery.
- **Three-monthly assessment** post-therapy to detect relapse.

Given the unpredictable course of HEV in transplant recipients and HIV patients, **regular viral and enzymatic surveillance** helps preempt hepatic deterioration.

4. Long-Term Biomarker Monitoring

For all patients' post-SVR or viral clearance:

- **Biannual transaminase and bilirubin tests** to monitor residual hepatic inflammation or fibrosis.
- **Annual albumin and PT tests** to assess long-term synthetic capacity.
- **Alpha-fetoprotein (AFP) and liver ultrasound** in cirrhotic patients to screen for hepatocellular carcinoma (HCC).

This long-term approach supports early intervention in case of disease recurrence or progression to malignancy.

5. Cost-Effective Pathways in Resource-Limited Settings

In LMICs, where molecular assays (PCR) may be unaffordable or unavailable:

- **ALT/AST and bilirubin tests** should be prioritized for frontline diagnostics.
- **Point-of-care transaminase tests** and dried blood spot PCRs can reduce infrastructural burdens.
- **Clinical scoring systems** like APRI (AST to Platelet Ratio Index) and FIB-4 should supplement biomarker data for fibrosis estimation.

Training primary care providers in **biomarker interpretation** and integrating digital health platforms for remote monitoring can further improve access and continuity of care.

Conclusion

Biomarker-driven surveillance provides a **clinically informative and economically feasible** framework for managing chronic hepatitis C and E infections. By tailoring diagnostic and monitoring strategies to **viral subtype, disease severity, and local resources**, healthcare

systems can ensure **early detection, timely treatment, and improved prognosis** for patients with RNA virus-associated chronic liver disease.

Diagnostic and Prognostic Utility in Clinical Settings

The interpretation of liver function biomarkers remains central to the **clinical assessment, staging, and prognosis** of chronic liver disease (CLD) due to RNA virus infections such as **Hepatitis C Virus (HCV)** and **Hepatitis E Virus (HEV)**. In the absence of liver biopsy or advanced imaging modalities—particularly in resource-limited settings—routine biochemical markers such as **ALT, AST, bilirubin, albumin**, and **prothrombin time (PT)** provide significant diagnostic and prognostic information.

1. ALT/AST Ratio and Fibrosis Progression

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are classic markers of hepatocellular injury. Their relative elevation offers insight into **disease stage**:

- **ALT > AST** is typically observed in early and moderate HCV infection, indicating **active necroinflammatory activity**.
- **AST ≥ ALT**, particularly with a ratio >1, is associated with **advanced fibrosis or cirrhosis**, reflecting mitochondrial AST leakage due to hepatocyte degeneration.
- Ratios >1.5–2 have been associated with poor prognosis, especially in alcohol-related co-pathology or long-standing HCV infection.

This ratio, when used in conjunction with other non-invasive scores (e.g., APRI, FIB-4), aids in fibrosis staging.

2. Bilirubin Elevation and Cholestasis

Elevated serum bilirubin, particularly the **direct (conjugated) fraction**, reflects **cholestasis or impaired hepatic excretion**. In the context of RNA virus-induced CLD:

- Mild elevation may accompany acute flares of HEV or HCV.
- **Persistent or progressive hyperbilirubinemia** is a hallmark of **intrahepatic cholestasis, bile duct injury, or cirrhosis**.
- Levels >3 mg/dL in compensated cirrhotics are linked with **transition to hepatic decompensation** and serve as a **MELD score component** for transplantation prioritization.

3. Serum Albumin Decline and Synthetic Dysfunction

Albumin, a hepatically synthesized plasma protein, reflects the **synthetic reserve of the liver**:

- Hypoalbuminemia (<3.5 g/dL) in chronic hepatitis indicates **ongoing hepatocellular damage** or impaired regeneration.
- Profound reductions (<2.8 g/dL) are predictive of **clinical decompensation**, such as ascites and edema, and correlate strongly with **Child-Pugh class B or C**.
- Serial albumin measurements track the **efficacy of antiviral therapy** and **overall nutritional status**.

Unlike transaminases, albumin levels decline slowly, making them reliable for **longitudinal prognostic evaluation**.

4. Prothrombin Time and Coagulation Status


The liver is central to the synthesis of coagulation factors. **Prolongation of PT (or elevated INR)** reflects severe hepatic dysfunction:

- PT >16 seconds or INR >1.5 denotes **impaired hepatic synthetic function**, typically seen in **advanced fibrosis or acute-on-chronic liver failure (ACLF)**.
- In chronic HEV or HCV, especially in immunocompromised or cirrhotic individuals, prolonged PT signals imminent **bleeding risk and need for urgent intervention**.
- Alongside bilirubin and albumin, PT is used in the **Child-Pugh scoring system** and **MELD model**, solidifying its role in transplant eligibility and prognosis.

Conclusion

ALT/AST ratio, bilirubin elevation, albumin decline, and PT prolongation serve not only as **diagnostic tools for liver injury and fibrosis** but also as **robust prognostic indicators** of disease progression and hepatic decompensation in RNA virus-related chronic liver disease. Their accessibility, cost-effectiveness, and clinical relevance make them indispensable in both primary and specialist hepatology practice.

ALT and AST levels across **low, moderate, and high viral load categories** in patients with chronic **HCV** and **HEV** infections. It highlights the trend of increasing enzyme levels with rising viral load, with consistently higher ALT levels in HCV compared to HEV.



Comparative Diagnostic Value of Liver Biomarkers in HCV and HEV-Associated Chronic Liver Disease

Biomarker	Function	HCV Trend	HEV Trend	Prognostic Value
ALT	Hepatocellular injury	Consistently elevated	Acutely elevated	Indicates ongoing hepatic inflammation
AST	Mitochondrial damage	Elevated (late-stage)	Variable	Correlates with necrosis, fibrosis
ALP	Cholestasis	Mild elevation	Marked in cholestasis	Detects intrahepatic obstruction
GGT	Bile duct activity	Elevated with alcohol/steatosis	Variable	Confirms hepatic cholestasis
Total Bilirubin	Excretion marker	Elevated in cirrhosis	Elevated in acute HEV	Marker of hepatic clearance function
Albumin	Synthetic function	Decreased in late CLD	Decreased in severe cases	Prognostic for hepatic decompensation
Prothrombin Time	Coagulopathy	Prolonged in cirrhosis	Prolonged in fulminant HEV	Predictor of liver failure risk

Summary

Liver biomarkers remain integral to the management of chronic viral hepatitis. While ALT and AST provide insights into ongoing hepatocyte injury, cholestatic and synthetic markers such as

ALP, GGT, bilirubin, albumin, and PT are critical in identifying cholestasis, fibrosis, and hepatic decompensation. The correlation between viral titers and enzymatic indices, though not absolute, provides a valuable prognostic compass when interpreted alongside clinical findings. Given the resource limitations in endemic areas, the rational application of biomarker surveillance may improve early detection and optimize therapeutic outcomes.

References

World Health Organization. Global hepatitis report 2022. Geneva: WHO; 2022.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2020.

Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014; 27(1):116–138.

Nguyen MH et al. Systematic review: Global prevalence of hepatitis C. Aliment Pharmacol Ther. 2022.

Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005.

Jothimani D et al. Fulminant hepatitis E in pregnancy. J Hepatol. 2021.

Wai CT et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003.

Degos F et al. Diagnostic accuracy of FibroScan and biochemical markers for liver fibrosis in chronic hepatitis C: A prospective study. Hepatology. 2010.

Ghany MG, Marks KM, Morgan TR. Hepatitis C guidance 2023 update: AASLD-IDSA. Hepatology. 2023.

Aggarwal R, Naik S. Epidemiology of hepatitis E: Past, present and future. Trop Gastroenterol. 2005.